Do analysts recommend EVMN or ICCC?

Evommune presently has a consensus target price of $45.63, indicating a potential upside of 264.65%. Given Evommune's stronger consensus rating and higher probable upside, analysts clearly believe Evommune is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evommune 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.79 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, EVMN or ICCC?

ImmuCell has higher revenue and earnings than Evommune. ImmuCell is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $13M 34.67 -$68.87M -$9.50 N/A ImmuCell $27.64M 3.63 -$1.04M -$0.06 N/A

Is EVMN or ICCC more profitable?

Evommune has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. Evommune's return on equity of 0.00% beat ImmuCell's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A ImmuCell -1.82% -1.88% -1.22%

Does the media prefer EVMN or ICCC?

In the previous week, Evommune had 8 more articles in the media than ImmuCell. MarketBeat recorded 9 mentions for Evommune and 1 mentions for ImmuCell. Evommune's average media sentiment score of 0.73 beat ImmuCell's score of 0.59 indicating that Evommune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmuCell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ICCC or PBYI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer ICCC or PBYI?

In the previous week, Puma Biotechnology had 2 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Puma Biotechnology and 1 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.59 beat Puma Biotechnology's score of 0.09 indicating that ImmuCell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend EOLS or ICCC?

Evolus currently has a consensus price target of $16.00, suggesting a potential upside of 166.00%. Given Evolus' stronger consensus rating and higher probable upside, equities research analysts clearly believe Evolus is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, EOLS or ICCC?

ImmuCell has lower revenue, but higher earnings than Evolus. ImmuCell is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evolus $297.18M 1.33 -$51.64M -$0.67 N/A ImmuCell $27.64M 3.63 -$1.04M -$0.06 N/A

Is EOLS or ICCC more profitable?

ImmuCell has a net margin of -1.82% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat ImmuCell's return on equity. Company Net Margins Return on Equity Return on Assets Evolus -14.39% N/A -19.03% ImmuCell -1.82% -1.88% -1.22%

Does the media refer more to EOLS or ICCC?

In the previous week, Evolus had 5 more articles in the media than ImmuCell. MarketBeat recorded 6 mentions for Evolus and 1 mentions for ImmuCell. Evolus' average media sentiment score of 1.02 beat ImmuCell's score of 0.59 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmuCell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TENX or ICCC?

Tenax Therapeutics presently has a consensus target price of $37.67, suggesting a potential upside of 178.79%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tenax Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor TENX or ICCC?

In the previous week, Tenax Therapeutics had 14 more articles in the media than ImmuCell. MarketBeat recorded 15 mentions for Tenax Therapeutics and 1 mentions for ImmuCell. Tenax Therapeutics' average media sentiment score of 0.76 beat ImmuCell's score of 0.59 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ImmuCell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AUTL or ICCC?

In the previous week, Autolus Therapeutics had 7 more articles in the media than ImmuCell. MarketBeat recorded 8 mentions for Autolus Therapeutics and 1 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.59 beat Autolus Therapeutics' score of 0.43 indicating that ImmuCell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmuCell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ImmuCell (ICCC) Competitors

$11.10 +0.06 (+0.54%)

As of 11:21 AM Eastern

Compare

ICCC vs. EVMN, PBYI, EOLS, TENX, and AUTL

Should you buy ImmuCell stock or one of its competitors? MarketBeat compares ImmuCell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImmuCell include Evommune (EVMN), Puma Biotechnology (PBYI), Evolus (EOLS), Tenax Therapeutics (TENX), and Autolus Therapeutics (AUTL).

How does ImmuCell compare to Evommune?

Evommune (NYSE:EVMN) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Evommune has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. Evommune's return on equity of 0.00% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
ImmuCell	-1.82%	-1.88%	-1.22%

Evommune presently has a consensus target price of $45.63, indicating a potential upside of 264.65%. Given Evommune's stronger consensus rating and higher probable upside, analysts clearly believe Evommune is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

13.5% of ImmuCell shares are owned by institutional investors. 31.1% of Evommune shares are owned by insiders. Comparatively, 5.7% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Evommune had 8 more articles in the media than ImmuCell. MarketBeat recorded 9 mentions for Evommune and 1 mentions for ImmuCell. Evommune's average media sentiment score of 0.73 beat ImmuCell's score of 0.59 indicating that Evommune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmuCell	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmuCell has higher revenue and earnings than Evommune. ImmuCell is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	34.67	-$68.87M	-$9.50	N/A
ImmuCell	$27.64M	3.63	-$1.04M	-$0.06	N/A

Summary

Evommune beats ImmuCell on 12 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Puma Biotechnology?

ImmuCell (NASDAQ:ICCC) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Puma Biotechnology has a net margin of 10.69% compared to ImmuCell's net margin of -1.82%. Puma Biotechnology's return on equity of 20.30% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Puma Biotechnology	10.69%	20.30%	12.05%

Puma Biotechnology has higher revenue and earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.63	-$1.04M	-$0.06	N/A
Puma Biotechnology	$228.40M	1.71	$31.11M	$0.48	15.95

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ImmuCell has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

In the previous week, Puma Biotechnology had 2 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Puma Biotechnology and 1 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.59 beat Puma Biotechnology's score of 0.09 indicating that ImmuCell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Puma Biotechnology beats ImmuCell on 12 of the 14 factors compared between the two stocks.

How does ImmuCell compare to Evolus?

Evolus (NASDAQ:EOLS) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

90.7% of Evolus shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 5.0% of Evolus shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Evolus has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

ImmuCell has lower revenue, but higher earnings than Evolus. ImmuCell is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.33	-$51.64M	-$0.67	N/A
ImmuCell	$27.64M	3.63	-$1.04M	-$0.06	N/A

In the previous week, Evolus had 5 more articles in the media than ImmuCell. MarketBeat recorded 6 mentions for Evolus and 1 mentions for ImmuCell. Evolus' average media sentiment score of 1.02 beat ImmuCell's score of 0.59 indicating that Evolus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmuCell	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmuCell has a net margin of -1.82% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
ImmuCell	-1.82%	-1.88%	-1.22%

Evolus currently has a consensus price target of $16.00, suggesting a potential upside of 166.00%. Given Evolus' stronger consensus rating and higher probable upside, equities research analysts clearly believe Evolus is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Evolus beats ImmuCell on 10 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

In the previous week, Tenax Therapeutics had 14 more articles in the media than ImmuCell. MarketBeat recorded 15 mentions for Tenax Therapeutics and 1 mentions for ImmuCell. Tenax Therapeutics' average media sentiment score of 0.76 beat ImmuCell's score of 0.59 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmuCell	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenax Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Tenax Therapeutics presently has a consensus target price of $37.67, suggesting a potential upside of 178.79%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tenax Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ImmuCell has higher revenue and earnings than Tenax Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A
ImmuCell	$27.64M	3.63	-$1.04M	-$0.06	N/A

Tenax Therapeutics has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-63.18%	-58.93%
ImmuCell	-1.82%	-1.88%	-1.22%

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Tenax Therapeutics beats ImmuCell on 10 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Autolus Therapeutics had 7 more articles in the media than ImmuCell. MarketBeat recorded 8 mentions for Autolus Therapeutics and 1 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.59 beat Autolus Therapeutics' score of 0.43 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmuCell	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Autolus Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Autolus Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 340.81%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Autolus Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ImmuCell has a net margin of -1.82% compared to Autolus Therapeutics' net margin of -311.98%. ImmuCell's return on equity of -1.88% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
ImmuCell	-1.82%	-1.88%	-1.22%

ImmuCell has lower revenue, but higher earnings than Autolus Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	7.01	-$287.53M	-$1.09	N/A
ImmuCell	$27.64M	3.63	-$1.04M	-$0.06	N/A

Summary

Autolus Therapeutics beats ImmuCell on 11 of the 17 factors compared between the two stocks.

Get ImmuCell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ICCC vs. The Competition

Export

Metric	ImmuCell	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$100.46M	$11.48B	$6.80B	$12.89B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-184.97	791.51	279.90	25.40
Price / Sales	3.63	946.50	648.58	114.39
Price / Cash	58.14	14.82	28.64	34.82
Price / Book	3.71	10.36	11.10	6.30
Net Income	-$1.04M	$2.80B	$3.48B	$347.60M
7 Day Performance	-1.25%	1.42%	1.93%	2.53%
1 Month Performance	7.87%	-3.36%	-3.29%	-2.57%
1 Year Performance	77.88%	154.79%	62.38%	20.26%

ImmuCell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ICCC ImmuCell	1.298 of 5 stars	$11.10 +0.5%	N/A	+84.0%	$100.46M	$27.64M	N/A	70	Positive News
EVMN Evommune	3.8576 of 5 stars	$11.04 -1.9%	$45.63 +313.2%	N/A	$397.70M	$13M	N/A	45	News Coverage Positive News Analyst Forecast
PBYI Puma Biotechnology	0.9696 of 5 stars	$7.81 -2.0%	N/A	+150.5%	$397.53M	$228.40M	16.27	200	Upcoming Earnings
EOLS Evolus	2.641 of 5 stars	$6.03 -3.1%	$16.00 +165.3%	-33.9%	$397.14M	$297.18M	N/A	170	News Coverage Positive News Upcoming Earnings
TENX Tenax Therapeutics	3.1652 of 5 stars	$14.82 -6.2%	$37.67 +154.2%	+130.4%	$393.10M	N/A	N/A	9	Earnings Report High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ICCC) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmuCell (ICCC) Competitors

ICCC vs. EVMN, PBYI, EOLS, TENX, and AUTL

How does ImmuCell compare to Evommune?

Summary

How does ImmuCell compare to Puma Biotechnology?

Summary

How does ImmuCell compare to Evolus?

Summary

How does ImmuCell compare to Tenax Therapeutics?

Summary

How does ImmuCell compare to Autolus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmuCell (ICCC) Competitors

ICCC vs. EVMN, PBYI, EOLS, TENX, and AUTL

How does ImmuCell compare to Evommune?

Is EVMN or ICCC more profitable?

Do analysts recommend EVMN or ICCC?

Do insiders and institutionals believe in EVMN or ICCC?

Does the media prefer EVMN or ICCC?

Which has better valuation & earnings, EVMN or ICCC?

Summary

How does ImmuCell compare to Puma Biotechnology?

Is ICCC or PBYI more profitable?

Which has better earnings and valuation, ICCC or PBYI?

Do institutionals and insiders hold more shares of ICCC or PBYI?

Which has more volatility and risk, ICCC or PBYI?

Does the media prefer ICCC or PBYI?

Do analysts prefer ICCC or PBYI?

Summary

How does ImmuCell compare to Evolus?

Do institutionals and insiders have more ownership in EOLS or ICCC?

Which has more volatility & risk, EOLS or ICCC?

Which has better valuation & earnings, EOLS or ICCC?

Does the media refer more to EOLS or ICCC?

Is EOLS or ICCC more profitable?

Do analysts recommend EOLS or ICCC?

Summary

How does ImmuCell compare to Tenax Therapeutics?

Does the media favor TENX or ICCC?

Which has more risk & volatility, TENX or ICCC?

Do analysts recommend TENX or ICCC?

Which has higher earnings and valuation, TENX or ICCC?

Is TENX or ICCC more profitable?

Do institutionals and insiders hold more shares of TENX or ICCC?

Summary

How does ImmuCell compare to Autolus Therapeutics?

Does the media favor AUTL or ICCC?

Do institutionals and insiders hold more shares of AUTL or ICCC?

Which has more volatility & risk, AUTL or ICCC?

Do analysts rate AUTL or ICCC?

Is AUTL or ICCC more profitable?

Which has preferable valuation & earnings, AUTL or ICCC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools